Phaseline

Targets › IPCS1

IPCS1: drug programs, companies and trials

1 program from 1 company in 4 trials: 2 Phase 3, 2 Phase 1; Genitourinary, Infectious disease, Other; next expected readout Mar 2027.

Open in Phaseline: the race on IPCS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Basilea Pharmaceuticafosmanogepix
GPI-anchored wall transfer protein 1 inhibitor
IPCS1, HMG1, FKS1Phase 3Candidemia; Invasive Mold Infections; Healthy Adult Participants; End Stage Renal Disease on DialysisMar 2027

Conditions

Candidemia (1) Invasive Mold Infections (1) Healthy Adult Participants (1) End Stage Renal Disease on Dialysis (1)

Modalities

small molecule (1)

Companies

Basilea Pharmaceutica (1)

Related targets

HMG1 (1) FKS1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.